Company news

Scancell Holdings PLC news in 2025

Scancell Holdings PLC's news releases, calls and decks from 2025, newest first.

View company

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

December 9, 2025

Continued improvement in PFS with iSCIB1+

December 9, 2025

Research Update

November 7, 2025

Result of AGM

October 30, 2025

Notice of AGM

October 3, 2025

Director Dealing

September 16, 2025

Final Results

September 11, 2025

Director/PDMR Shareholding

August 4, 2025

Strong Phase 2 data on iSCIB1+ in Melanoma

July 22, 2025

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

July 22, 2025

Share Option Exercise

July 16, 2025

Scancell initiates new arm in SCOPE Phase 2 study

June 25, 2025

Investor Update via Investor Meet Company.

April 22, 2025

Partnership with NHS Cancer Vaccine Launch Pad

April 14, 2025

Scancell to present at 2025 AACR Annual Meeting

April 1, 2025

Issue of share options

February 20, 2025

Scancell presenting at AACR IO conference

February 17, 2025

Interim Results

January 30, 2025

Notice of Interim Results

January 23, 2025

Modi-1 Vaccine Achieves Early Clinical Validation

January 9, 2025

Calls in 2025

Decks in 2025